Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Aya Nakaya; Hirohiko Shibayama; Nobuhiko Uoshima; Ryosuke Yamamura; Satoshi Yoshioka; Kazunori Imada; Yuji Shimura; Masaaki Hotta; Toshimitsu Matsui; Satoru Kosugi; Hitoshi Hanamoto; Hitoji Uchiyama; Satoshi Yoshihara; Shin-Ichi Fuchida; Yoshiyuki Onda; Yasuhiro Tanaka; Kensuke Ohta; Mitsuhiro Matsuda; Junya Kanda; Adachi Yoko; Miki Kiyota; Eri Kawata; Ryoichi Takahashi; Kentaro Fukushima; Hirokazu Tanaka; Hideo Yagi; Teruhito Takakuwa; Naoki Hosen; Tomoki Ito; Chihiro Shimazaki; Akifumi Takaori-Kondo; Junya Kuroda; Itaru Matsumura; Masayuki Hino

doi:10.1016/j.lrr.2023.100395

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Leuk Res Rep. 2023 Nov 17:20:100395. doi: 10.1016/j.lrr.2023.100395. eCollection 2023.

Authors

Aya Nakaya^{1

2}, Hirohiko Shibayama^{1

2}, Nobuhiko Uoshima^{3

2}, Ryosuke Yamamura^{4

2}, Satoshi Yoshioka^{5

2}, Kazunori Imada^{5

2}, Yuji Shimura^{6

2}, Masaaki Hotta^{7

2}, Toshimitsu Matsui^{8

2}, Satoru Kosugi^{9

2}, Hitoshi Hanamoto^{10

2}, Hitoji Uchiyama^{11

2}, Satoshi Yoshihara^{12

2}, Shin-Ichi Fuchida^{13

2}, Yoshiyuki Onda^{14

2}, Yasuhiro Tanaka^{15

2}, Kensuke Ohta^{16

2}, Mitsuhiro Matsuda^{17

2}, Junya Kanda^{18

2}, Adachi Yoko^{19

2}, Miki Kiyota^{20

2}, Eri Kawata^{20

2}, Ryoichi Takahashi^{21

2}, Kentaro Fukushima^{22

2}, Hirokazu Tanaka^{23

2}, Hideo Yagi^{24

2}, Teruhito Takakuwa^{25

2}, Naoki Hosen^{22

2}, Tomoki Ito^{7

2}, Chihiro Shimazaki^{13

2}, Akifumi Takaori-Kondo^{8

2}, Junya Kuroda^{6

2}, Itaru Matsumura^{23

2}, Masayuki Hino^{25

2}

Affiliations

¹ Department of Hematology, National Hospital Organization Osaka National Hospital, Japan.
² Kansai Myeloma Forum, Japan.
³ Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Japan.
⁴ Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Japan.
⁵ Department of Hematology, Japanese Red Cross Osaka Hospital, Japan.
⁶ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
⁷ First Department of Internal Medicine, Kansai Medical University, Japan.
⁸ Department of Hematology, Nishiwaki Municipal Hospital, Japan.
⁹ Department of Hematology, Toyonaka Municipal Hospital, Japan.
¹⁰ Department of Hematology, Kindai University Nara Hospital, Japan.
¹¹ Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Japan.
¹² Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Japan.
¹³ Department of Hematology, Japan Community Healthcare Organization Kyoto Kuramaguchi Medical Center, Japan.
¹⁴ Department of Hematology, Japanese Red Cross Takatsuki Hospital, Japan.
¹⁵ Department of Hematology, Japanese Red Cross Wakayama Medical Center, Japan.
¹⁶ Hematology Ohta Clinic, Shinsaibashi, Japan.
¹⁷ Department of Hematology, PL General Hospital, Japan.
¹⁸ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University.
¹⁹ Department of Internal Medicine, Japan Community Healthcare Organization Kobe Central Hospital, Japan.
²⁰ Department of Hematology, Matsushita Memorial Hospital, Japan.
²¹ Department of Hematology, Omihachiman Community Medical Center, Japan.
²² Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan.
²³ Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan.
²⁴ Department of Hematology and Oncology, Nara Prefecture General Medical Center, Japan.
²⁵ Hematology, Graduate School of Medicine, Osaka Metropolitan University, Japan.

Abstract

To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (n = 338, 72 %) was 6.5 years, patients with del(17p) (n = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (n = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (n = 18, 4 %) was 2.1 years (p = 0.032). Patients with double-positive CAs had a significantly worse prognosis.

Keywords: Double-positive; High-risk chromosomal abnormality; Multiple myeloma; Real-world.